Navigation Links
Resverlogix is Presenting at IAS HDL Workshop
Date:10/11/2007

Novel ApoA-I/HDL raising drug, RVX-208, to be featured in oral presentation

TSX Exchange Symbol: RVX

CALGARY, Oct. 11 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tomorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that raises apolipoprotein A-I and HDL in vitro and in vivo" will be presented by Dr. Norman Wong, Resverlogix Co-Founder and Chairman of the Scientific Advisory Board on October 12th at the Petros M. Nomikos Conference Center in Santorini, Greece.

"This meeting of the IAS attracts internationally elite scientists in cardiovascular medicine. This venue is ideal for announcing the favorable and novel features of RVX-208, scheduled for clinical trials later this year," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. Dr. Johansson added, "RVX-208 is a small molecule for oral administration that has shown to have unprecedented effects in raising ApoA-I and functional HDL. There is an ever-increasing body of evidence from predictive animal models that indicates RVX-208's potential for preventing and regressing atherosclerosis. We are very happy to participate in this important conference."

Mr. Donald McCaffrey, President and CEO of Resverlogix said, "These highly regarded researchers who will be participating at the event clearly understand that there is a large unmet medical need in cardiovascular disease (CVD). There is a lot of excitement among these key opinion leaders that Resverlogix's novel small molecule drug could address many of the shortcomings of current CVD drugs."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that

reflect the current views and/or expectations of Resverlogix Corp. with

respect to its performance, business and future events. Such statements

are subject to a number of risks, uncertainties and assumptions. Actual

results and events may vary significantly. The TSX Exchange does not

accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... different cell type. Many treatments for specific cancers, such as breast, prostate, or ... treatment is androgen deprivation therapy for advanced prostate cancer. , This therapy ...
(Date:8/16/2017)... year,s edition of the Inc. 5000 features a now-familiar name: BioPoint ( ... the list for the third year in a row. Now in its ... on a set of quantitative metrics. In addition, BioPoint was also named ... Bay State . ... 5000 ...
(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...
(Date:8/15/2017)... ... , ... The Conference Forum and The Trout Group ... of upcoming panels and events. The partnership culminates with the 4th Annual IO360° ... York City. , “With our experience in producing the Immuno-Oncology 360° NYC event and ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):